LT3716992T - Vegf antagonisto panaudojimas akių angiogeninių sutrikimų gydymui - Google Patents

Vegf antagonisto panaudojimas akių angiogeninių sutrikimų gydymui

Info

Publication number
LT3716992T
LT3716992T LTEPPCT/US2018/063025T LTUS2018063025T LT3716992T LT 3716992 T LT3716992 T LT 3716992T LT US2018063025 T LTUS2018063025 T LT US2018063025T LT 3716992 T LT3716992 T LT 3716992T
Authority
LT
Lithuania
Prior art keywords
vegf antagonist
eye disorders
angiogenic eye
treat angiogenic
treat
Prior art date
Application number
LTEPPCT/US2018/063025T
Other languages
English (en)
Inventor
Robert L. Vitti
Alyson J. BERLINER
Karen Chu
Original Assignee
Regeneron Pharmaceuticals, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=64755724&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=LT3716992(T) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Regeneron Pharmaceuticals, Inc. filed Critical Regeneron Pharmaceuticals, Inc.
Publication of LT3716992T publication Critical patent/LT3716992T/lt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
LTEPPCT/US2018/063025T 2017-11-30 2018-11-29 Vegf antagonisto panaudojimas akių angiogeninių sutrikimų gydymui LT3716992T (lt)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201762593033P 2017-11-30 2017-11-30
US201862644425P 2018-03-17 2018-03-17
US201862748782P 2018-10-22 2018-10-22
PCT/US2018/063025 WO2019108770A1 (en) 2017-11-30 2018-11-29 Use of a vegf antagonist to treat angiogenic eye disorders

Publications (1)

Publication Number Publication Date
LT3716992T true LT3716992T (lt) 2022-09-12

Family

ID=64755724

Family Applications (1)

Application Number Title Priority Date Filing Date
LTEPPCT/US2018/063025T LT3716992T (lt) 2017-11-30 2018-11-29 Vegf antagonisto panaudojimas akių angiogeninių sutrikimų gydymui

Country Status (22)

Country Link
US (2) US10973879B2 (lt)
EP (3) EP4122486A1 (lt)
JP (2) JP7339248B2 (lt)
KR (1) KR20200093621A (lt)
CN (1) CN111465407A (lt)
AU (1) AU2018375398A1 (lt)
BR (1) BR112020010659A2 (lt)
CA (1) CA3083611A1 (lt)
DK (1) DK3716992T3 (lt)
ES (1) ES2927049T3 (lt)
HR (1) HRP20221335T1 (lt)
HU (1) HUE059827T2 (lt)
IL (1) IL274711A (lt)
LT (1) LT3716992T (lt)
MX (1) MX2020005166A (lt)
PL (1) PL3716992T3 (lt)
PT (1) PT3716992T (lt)
RS (1) RS63703B1 (lt)
SG (1) SG11202004268PA (lt)
SI (1) SI3716992T1 (lt)
WO (1) WO2019108770A1 (lt)
ZA (1) ZA202002821B (lt)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SMP200800060B (it) 2006-04-07 2009-07-14 Procter & Gamble Anticorpi che legano la proteina umana tirosina fosfatasi beta (hptbeta) e loro usi
KR20200077622A (ko) 2011-01-13 2020-06-30 리제너론 파아마슈티컬스, 인크. 혈관신생 눈 장애를 치료하기 위한 vegf 길항제의 용도
FI3384049T3 (fi) 2015-12-03 2023-09-25 Regeneron Pharma Menetelmiä geenimuunnosten liittämiseksi kliiniseen tulokseen potilailla, jotka kärsivät silmänpohjan ikärappeumasta ja joita on hoidettu anti-VEGF:llä
MX2020005166A (es) 2017-11-30 2020-09-03 Regeneron Pharma Uso de un antagonista de vegf para tratar trastornos oculares angiogenicos.
JP7235770B2 (ja) 2018-05-10 2023-03-08 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 高濃度ｖｅｇｆ受容体融合タンパク質を含む製剤
US11519020B2 (en) 2018-05-25 2022-12-06 Regeneron Pharmaceuticals, Inc. Methods of associating genetic variants with a clinical outcome in patients suffering from age-related macular degeneration treated with anti-VEGF
US10894824B2 (en) 2018-09-24 2021-01-19 Aerpio Pharmaceuticals, Inc. Multispecific antibodies that target HPTP-β (VE-PTP) and VEGF
US10975169B1 (en) * 2019-09-27 2021-04-13 Memorial Sloan Kettering Cancer Center Methods for treating diabetic retinopathy using anti-ceramide monoclonal antibody 2A2
US11944663B2 (en) * 2020-06-18 2024-04-02 Chengdu Kanghong Biotechnologies Co. Ltd. Method for treating angiogenic eye disorders using VEGF antagonists
KR20240008821A (ko) * 2021-05-17 2024-01-19 리제너론 파아마슈티컬스, 인크. 혈관신생성 눈 장애 치료를 위한 연장된 고용량 vegf 길항제 요법
WO2023177689A1 (en) * 2022-03-15 2023-09-21 Regeneron Pharmaceuticals, Inc. Extended, high dose vegf antagonist regimens for treatment of angiogenic eye disorders

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL146890A0 (en) 1999-06-08 2002-08-14 Regeneron Pharma Modified chimeric polypeptides with improved pharmacokinetic properties
US7306799B2 (en) * 1999-06-08 2007-12-11 Regeneron Pharmaceuticals, Inc. Use of VEGF inhibitors for treatment of eye disorders
US7396664B2 (en) 1999-06-08 2008-07-08 Regeneron Pharmaceuticals, Inc. VEGF-binding fusion proteins and nucleic acids encoding the same
US7303746B2 (en) 1999-06-08 2007-12-04 Regeneron Pharmaceuticals, Inc. Methods of treating eye disorders with modified chimeric polypeptides
US7070959B1 (en) 1999-06-08 2006-07-04 Regeneron Pharmaceuticals, Inc. Modified chimeric polypeptides with improved pharmacokinetic properties
US6833349B2 (en) 1999-06-08 2004-12-21 Regeneron Pharmaceuticals, Inc. Methods of treating inflammatory skin diseases
US7087411B2 (en) 1999-06-08 2006-08-08 Regeneron Pharmaceuticals, Inc. Fusion protein capable of binding VEGF
US7300563B2 (en) 2003-02-07 2007-11-27 Pavco, Inc. Use of N-alllyl substituted amines and their salts as brightening agents in nickel plating baths
SI1802334T1 (sl) 2004-10-21 2012-12-31 Genentech, Inc. Postopek za zdravljenje intraokularnih neovaskularnih bolezni
WO2006088650A2 (en) 2005-02-02 2006-08-24 Regeneron Pharmaceuticals, Inc. Method of treating eye injury with local administration of a vegf inhibitor
KR20200077622A (ko) 2011-01-13 2020-06-30 리제너론 파아마슈티컬스, 인크. 혈관신생 눈 장애를 치료하기 위한 vegf 길항제의 용도
JP2016522250A (ja) 2013-06-20 2016-07-28 ノバルティス アーゲー 黄斑浮腫の治療におけるｖｅｇｆアンタゴニストの使用
WO2017053807A2 (en) 2015-09-23 2017-03-30 Genentech, Inc. Optimized variants of anti-vegf antibodies
EP3377100A1 (en) * 2015-11-18 2018-09-26 Formycon AG Pre-filled pharmaceutical package comprising a liquid formulation of a vegf-antagonist
MX2020005166A (es) 2017-11-30 2020-09-03 Regeneron Pharma Uso de un antagonista de vegf para tratar trastornos oculares angiogenicos.
JP7235770B2 (ja) 2018-05-10 2023-03-08 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 高濃度ｖｅｇｆ受容体融合タンパク質を含む製剤

Also Published As

Publication number Publication date
SI3716992T1 (sl) 2022-10-28
KR20200093621A (ko) 2020-08-05
EP4279135A2 (en) 2023-11-22
JP2021505535A (ja) 2021-02-18
CN111465407A (zh) 2020-07-28
JP7339248B2 (ja) 2023-09-05
CA3083611A1 (en) 2019-06-06
IL274711A (en) 2020-07-30
US10973879B2 (en) 2021-04-13
WO2019108770A1 (en) 2019-06-06
ES2927049T3 (es) 2022-11-02
PL3716992T3 (pl) 2022-12-19
HUE059827T2 (hu) 2023-01-28
US20190290725A1 (en) 2019-09-26
BR112020010659A2 (pt) 2020-11-10
HRP20221335T1 (hr) 2022-12-23
JP2023159323A (ja) 2023-10-31
EP4279135A3 (en) 2024-02-21
SG11202004268PA (en) 2020-06-29
EP3716992B1 (en) 2022-08-10
RS63703B1 (sr) 2022-11-30
AU2018375398A1 (en) 2020-06-18
PT3716992T (pt) 2022-08-31
ZA202002821B (en) 2021-08-25
EP3716992A1 (en) 2020-10-07
DK3716992T3 (da) 2022-09-12
EP4122486A1 (en) 2023-01-25
US20210205410A1 (en) 2021-07-08
MX2020005166A (es) 2020-09-03

Similar Documents

Publication Publication Date Title
IL274711A (en) Use of a vegf antagonist to treat angiogenic eye disorders
IL260167A (en) For the treatment of vegf disorders - use of an agonist for angiogenic eyes
HK1231417A1 (zh) 用於治療眼科疾病和障礙的化合物
IL249602A0 (en) Methods and devices for the treatment of posterior ocular disorders
GB201610695D0 (en) Eye massaging device
SG11201506309SA (en) Eye massager
TWD174587S (zh) 按摩裝置之部分
SG11201608257RA (en) A device for a medical treatment of a sclera
ZA201702403B (en) Sphingosine-1-phospate receptor modulators for treatment of cardiopulmonary disorders
IL267229A (en) Methods of treating ocular disorders
HK1205924A1 (en) Eye massager
HK1222535A1 (zh) 下肢用按摩器
IL259153A (en) Use of proteasome inhibitors to treat ocular disorders
IL271164A (en) Use of vibragron to treat overactive bladder
EP3574907C0 (en) AN NK1/NK3 RECEPTOR ANTAGONIST FOR THE TREATMENT OF SEX HORMONE-DEPENDENT DISEASES
IL270362B (en) Glaucoma treatment
SG11202001595SA (en) Angio-3 for treatment of retinal angiogenic diseases
GB201607388D0 (en) Treatment of impulsivity-related disorders
PL3047824T3 (pl) Urządzenie do laserowej terapii ludzkiego oka
HK1220144A1 (zh) -叔丁基-苄基 -氯- -氯- -乙基-苯基 -乙基 -氟- -三氟甲基-苯甲酰胺用於治療眼疾病的用途
EP3506925C0 (en) USE OF CGRP RECEPTOR ANTAGONISTS IN THE TREATMENT OF GLAUCOMA
GB201604359D0 (en) Treatment of tissue disorders
SG11201709221QA (en) Lower limb exercise assisting device
IL234962A0 (en) Use of substances to treat fat-related diseases
GB201602641D0 (en) Treatment of fibrotic disorders